Wednesday, July 8, 2026

biotech · Major Depressive Disorder · Schizophrenia · NBIX

NEUROCRINE BIOSCIENCES

NEUROCRINE BIOSCIENCES is a biotech organization headquartered in San Diego, USA. It trades on NYSE under ticker NBIX. Primary therapeutic focus areas include Major Depressive Disorder, Schizophrenia, Congenital Adrenal

6027 Edgewood Bend Ct, San Diego, California 92130, US HQ
1992 Founded
2,307 Employees
Public company Type
NBIX · NYSE Ticker
Company details
Status
Public
HQ
6027 Edgewood Bend Ct, San Diego, California 92130, US
Founded
1992
Employees
2,307
Programs
79
Drugs
28
Patents
111
Clinical program

Valbenazine Oral Capsule

Approved · small molecule · Tardive Dyskinesia

Valbenazine Oral Capsule for Tardive Dyskinesia is a Approved program (small_molecule) at NEUROCRINE BIOSCIENCES INC with 1 ClinicalTrials.gov record(s).

← All NEUROCRINE BIOSCIENCES INC projects Approved small molecule terminated

Internal code STUDY20221555

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
NEUROCRINE BIOSCIENCES INC
Phase
Approved
Modality
small_molecule
Indication
Tardive Dyskinesia
Status
terminated
Trials
1